Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASCENDIS PHARMA A/S

(ASND)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
157.4(c) 153.54(c) 157.32(c) 159.22(c) 161.51(c) Last
99 484 268 673 142 375 118 129 295 266 Volume
+1.92% -2.45% +2.46% +1.21% +1.44% Change
More quotes
Estimated financial data (e)
Sales 2021 11,6 M 13,6 M 13,6 M
Net income 2021 -439 M -514 M -514 M
Net cash position 2021 378 M 444 M 444 M
P/E ratio 2021 -17,0x
Yield 2021 -
Sales 2022 85,9 M 101 M 101 M
Net income 2022 -452 M -530 M -530 M
Net cash position 2022 235 M 275 M 275 M
P/E ratio 2022 -17,2x
Yield 2022 -
Capitalization 7 829 M 9 180 M 9 180 M
EV / Sales 2021 641x
EV / Sales 2022 88,4x
Nbr of Employees 482
Free-Float 10,6%
More Financials
Company
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto,... 
More about the company
Ratings of Ascendis Pharma A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ASCENDIS PHARMA A/S
09/16ASCENDIS PHARMA A/S : Articles of Association (Form 6-K)
PU
09/07ASCENDIS PHARMA A/S : Seeks FDA Nod to Start TransCon Trial in Patients with Adv..
MT
09/07Ascendis Pharma A/S Announces Upcoming Investor Presentations
GL
09/07Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate ..
GL
09/07Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate ..
CI
09/07European ADRs Move Lower in Tuesday Trading
MT
09/02European ADRs Move Higher in Thursday Trading
MT
09/02ASCENDIS PHARMA A/S : Prices Offering at $160 Per ADS
MT
09/01Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
GL
09/01Health Care Stocks Reverse Losses as Biotechs Rise
MT
09/01ADRs End Mostly Higher, Ascendis Pharma Trades Actively
DJ
09/01Health Care Stocks Edging Lower, Biotechs Working to Limit Declines
MT
09/01Health Care Stocks Inch Higher Ahead of Wednesday Open
MT
08/31ASCENDIS PHARMA A/S : Launches Share Offering -- Stock Down 4% After-Hours
MT
08/31Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
GL
More news
News in other languages on ASCENDIS PHARMA A/S
09/07Ascendis Pharma demande l'autorisation de la FDA pour lancer l'essai TransCon..
09/07Les ADR européens en baisse mardi
09/02Les ADR européens sont en hausse jeudi
09/02Ascendis Pharma fixe le prix de son offre à 160 $ par ADS
09/01Les actions du secteur de la santé inversent leurs pertes alors que les biote..
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | ASND | US04351P1012 | MarketScreener
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 137,75 €
Average target price 163,49 €
Spread / Average Target 18,7%
EPS Revisions
Managers and Directors
Jan Møller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Kennett Sprogøe Senior Vice President, Head-Innovation & Research
Mark A. Bach Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-3.16%9 180
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850